Evidence-based recommendations on obeticholic acid (Ocaliva) for treating primary biliary cholangitis (CBC / cirrhosis) in adults
Evidence-based recommendations on ixekizumab (Taltz) for moderate to severe plaque psoriasis in adults
Evidence-based recommendations on pegylated liposomal irinotecan (Onivyde) for treating pancreatic cancer after gemcitabine
This guideline covers condom distribution schemes. The aim is to reduce the risk of sexually transmitted infections (STIs). In addition, these schemes can provide a good introduction to broader sexual and reproductive health services, especially for younger people, and help prevent unplanned pregnancies.
This guideline covers medicines support for adults (aged 18 and over) who are receiving social care in the community. It aims to ensure that people who receive social care are supported to take and look after their medicines effectively and safely at home. It gives advice on assessing if people need help with managing their medicines, who should provide medicines support and how health and social care staff should work together.
NICE is unable to make a recommendation about the use in the NHS of alectinib for anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
NICE is unable to recommend the use in the NHS of panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer..
This guideline covers good practice for developing, authorising, using and updating patient group directions. It also offers advice on deciding whether a patient group direction is needed.
NICE is unable to make a recommendation about the use of ibrutinib with bendamustine and rituximab for relapsed or refractory chronic lymphocytic leukaemia
NICE was unable to make a recommendation about the use in the NHS of bevacizumab for epidermal growth factor receptor mutation-positive non-small-cell lung
NICE was unable to make a recommendation about the use in the NHS of tenofovir alafenamide for treating chronic hepatitis B because no evidence submission was
NICE was unable to make a recommendation about the use in the NHS of elotuzumab for previously treated multiple myeloma because no evidence submission was
Evidence-based recommendations on ustekinumab (Stelara) for treating active psoriatic arthritis in adults
Evidence-based recommendations on ustekinumab (Stelara) for treating moderate to severe psoriasis in adults
Evidence-based recommendations on apremilast (Otezla) for treating active psoriatic arthritis in adults
Evidence-based recommendations on everolimus (Afinitor) for advanced renal cell carcinoma (kidney cancer) after previous treatment
This guideline covers targeted interventions to prevent misuse of drugs, including illegal drugs, ‘legal highs’ and prescription-only medicines. It aims to prevent or delay harmful use of drugs in children, young people and adults who are most likely to start using drugs or who are already experimenting or using drugs occasionally.